Literature DB >> 2725806

Amyotrophic lateral sclerosis severity scale.

A D Hillel1, R M Miller, K Yorkston, E McDonald, F H Norris, N Konikow.   

Abstract

The amyotrophic lateral sclerosis (ALS) severity scale has been developed to provide an ordinal staging system and a means of rapid functional assessment for patients with ALS. The scale allows an examiner to evaluate the symptoms of ALS numerically in four categories that describe speech, swallowing, lower extremity, and upper extremity abilities. These scores, combined with a vital capacity measured on a hand-held respirometer, provide a rapid, accurate assessment of a patient's disease status and can be used for treatment planning. The ALS severity scale has been shown to have an average estimated reliability coefficient of 0.95 between examiners. Speech ratings were correlated greater than 0.80 for objective speech measures. Rates of progression of the total score in a small group of patients ranged from -3.4 to -24.0 points/year with a mean of -11.3 points/year.

Entities:  

Mesh:

Year:  1989        PMID: 2725806     DOI: 10.1159/000110176

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  42 in total

1.  Effects of lumbar sympathetic ganglion block for a patient with amyotrophic lateral sclerosis (ALS).

Authors:  Takeshi Kitoh; Koichi Kobayashi; Hiroaki Ina; Yukihiro Ofusa; Tetsutaro Otagiri; Satoshi Tanaka; Koichi Ono
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

2.  Peripheral nerve block in a patient with amyotrophic lateral sclerosis.

Authors:  Nezih Sertöz; Semra Karaman
Journal:  J Anesth       Date:  2011-11-01       Impact factor: 2.078

3.  Riluzole does not have an acute effect on motor thresholds and the intracortical excitability in amyotrophic lateral sclerosis.

Authors:  M Sommer; F Tergau; S Wischer; C D Reimers; W Beuche; W Paulus
Journal:  J Neurol       Date:  1999-11       Impact factor: 4.849

4.  Diffusion tensor imaging-based fractional anisotropy quantification in the corticospinal tract of patients with amyotrophic lateral sclerosis using a probabilistic mixture model.

Authors:  S K Schimrigk; B Bellenberg; M Schlüter; B Stieltjes; R Drescher; J Rexilius; C Lukas; H K Hahn; H Przuntek; O Köster
Journal:  AJNR Am J Neuroradiol       Date:  2007-04       Impact factor: 3.825

5.  Signs of impaired selective attention in patients with amyotrophic lateral sclerosis.

Authors:  Elmar H Pinkhardt; Reinhart Jürgens; Wolfgang Becker; Matthias Mölle; Jan Born; Albert C Ludolph; Herbert Schreiber
Journal:  J Neurol       Date:  2008-02-18       Impact factor: 4.849

6.  Pilot study of intravenous immunoglobulin in HIV-associated myelopathy.

Authors:  Katia Cikurel; Lauren Schiff; David M Simpson
Journal:  AIDS Patient Care STDS       Date:  2009-02       Impact factor: 5.078

7.  Management of oral-pharyngeal dysphagia symptoms in amyotrophic lateral sclerosis.

Authors:  E A Strand; R M Miller; K M Yorkston; A D Hillel
Journal:  Dysphagia       Date:  1996       Impact factor: 3.438

8.  Assessment of autonomic symptoms in a medically complex, urban patient population.

Authors:  Jessica Robinson-Papp; Sandeep K Sharma; Mary Catherine George; David M Simpson
Journal:  Clin Auton Res       Date:  2016-10-12       Impact factor: 4.435

9.  Continuous response variable trial design in motor neuron disease: long term treatment with a TRH analogue (RX77368).

Authors:  A Goonetilleke; R J Guiloff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

10.  Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy.

Authors:  Karsten Schepelmann; Yaroslav Winter; Annika E Spottke; Detlef Claus; Christoph Grothe; Rolf Schröder; Dieter Heuss; Stefan Vielhaber; Veit Mylius; Reinhard Kiefer; Bertold Schrank; Wolfgang H Oertel; Richard Dodel
Journal:  J Neurol       Date:  2009-07-24       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.